PriceTargets.com logo

IGM Biosciences - IGMS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $17.75
  • Forecasted Upside: 157.25%
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$6.90 As of 12/20/2024 06:45 PM ET
▼ -0.15 (-2.13%)

This chart shows the closing price for IGMS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IGM Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IGMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IGMS

Analyst Price Target is $17.75
▲ +157.25% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for IGM Biosciences in the last 3 months. The average price target is $17.75, with a high forecast of $27.00 and a low forecast of $9.00. The average price target represents a 157.25% upside from the last price of $6.90.

This chart shows the closing price for IGMS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 investment analysts is to moderate buy stock in IGM Biosciences. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/6/2024BMO Capital MarketsInitiated CoverageOutperform$21.00
11/11/2024Stifel NicolausBoost TargetBuy ➝ Buy$25.00 ➝ $27.00
10/18/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$17.00 ➝ $20.00
10/1/2024GuggenheimLower TargetBuy ➝ Buy$25.00 ➝ $20.00
10/1/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$20.00 ➝ $17.00
10/1/2024WedbushLower TargetOutperform ➝ Outperform$25.00 ➝ $22.00
10/1/2024JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$12.00 ➝ $9.00
10/1/2024Truist FinancialDowngradeBuy ➝ Hold$24.00 ➝ $12.00
9/5/2024HC WainwrightLower TargetNeutral ➝ Neutral$12.00 ➝ $11.00
8/23/2024Truist FinancialLower TargetBuy ➝ Buy$25.00 ➝ $24.00
8/15/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$20.00 ➝ $20.00
8/15/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$11.00 ➝ $12.00
8/14/2024WedbushReiterated RatingOutperform ➝ Outperform$20.00 ➝ $25.00
5/24/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$12.00 ➝ $12.00
5/9/2024WedbushReiterated RatingOutperform ➝ Outperform$20.00
4/18/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$12.00
2/9/2024Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$9.00 ➝ $21.00
12/15/2023Bank of AmericaDowngradeBuy ➝ Neutral$8.00
12/7/2023HC WainwrightDowngradeBuy ➝ Neutral$11.00 ➝ $7.00
12/6/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$8.00 ➝ $9.00
11/15/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$15.00 ➝ $8.00
11/15/2023HC WainwrightLower TargetBuy ➝ Buy$17.00 ➝ $11.00
11/14/2023Stifel NicolausLower TargetBuy ➝ Buy$26.00 ➝ $25.00
11/14/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$11.00 ➝ $8.00
11/14/2023WedbushReiterated RatingOutperform$19.00 ➝ $16.00
9/6/2023Truist FinancialReiterated RatingBuy ➝ Buy$25.00
8/17/2023Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$11.00
8/8/2023Stifel NicolausLower Target$49.00 ➝ $26.00
8/7/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$20.00 ➝ $15.00
8/7/2023Needham & Company LLCReiterated RatingBuy ➝ Hold
8/7/2023HC WainwrightLower TargetBuy ➝ Buy$22.00 ➝ $17.00
8/7/2023Robert W. BairdLower Target$31.00 ➝ $17.00
8/7/2023GuggenheimLower Target$38.00 ➝ $25.00
8/4/2023WedbushReiterated RatingOutperform$37.00 ➝ $19.00
5/15/2023GuggenheimLower Target$40.00 ➝ $38.00
5/15/2023Royal Bank of CanadaLower Target$21.00 ➝ $17.00
4/4/2023Truist FinancialLower TargetBuy$37.00 ➝ $25.00
4/3/2023JPMorgan Chase & Co.Lower TargetNeutral$27.00 ➝ $26.00
4/3/2023Morgan StanleyLower TargetEqual Weight$30.00 ➝ $20.00
4/3/2023HC WainwrightLower TargetBuy$45.00 ➝ $22.00
3/31/2023Royal Bank of CanadaLower TargetSector Perform$24.00 ➝ $21.00
11/9/2022Jefferies Financial GroupReiterated RatingBuy$61.00 ➝ $55.00
11/7/2022HC WainwrightLower TargetBuy$58.00 ➝ $45.00
11/4/2022Royal Bank of CanadaLower TargetSector Perform$27.00 ➝ $22.00
10/17/2022JPMorgan Chase & Co.Initiated CoverageNeutral$27.00
8/29/2022Bank of AmericaInitiated CoverageBuy$34.00
8/23/2022Truist FinancialLower TargetBuy$74.00 ➝ $37.00
8/15/2022GuggenheimLower Target$40.00
6/1/2022Robert W. BairdLower TargetOutperform$46.00 ➝ $31.00
5/17/2022HC WainwrightLower TargetBuy$59.00 ➝ $58.00
4/4/2022Robert W. BairdLower TargetOutperform ➝ Outperform$65.00 ➝ $46.00
3/31/2022WedbushLower Target$67.00 ➝ $58.00
3/31/2022HC WainwrightLower TargetBuy$76.00 ➝ $59.00
3/30/2022Truist FinancialLower TargetBuy$80.00 ➝ $74.00
3/30/2022Morgan StanleyBoost TargetEqual Weight$25.00 ➝ $30.00
1/3/2022GuggenheimLower Target$100.00 ➝ $55.00
12/16/2021HC WainwrightReiterated RatingBuy$114.00 ➝ $76.00
12/14/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$100.00 ➝ $38.00
12/14/2021Robert W. BairdLower TargetOutperform ➝ Outperform$90.00 ➝ $65.00
12/13/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$100.00 ➝ $38.00
12/13/2021Jefferies Financial GroupBoost TargetBuy$101.00 ➝ $126.00
12/13/2021Stifel NicolausLower TargetBuy ➝ Buy$98.00 ➝ $65.00
12/13/2021WedbushLower TargetOutperform ➝ Outperform$82.00 ➝ $67.00
12/13/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$90.00 ➝ $51.00
11/5/2021Royal Bank of CanadaLower TargetOutperform$110.00 ➝ $90.00
11/5/2021WedbushUpgradeNeutral ➝ Outperform$82.00
8/26/2021Morgan StanleyInitiated CoverageOverweight$100.00
8/16/2021WedbushBoost TargetNeutral$77.00 ➝ $82.00
8/10/2021HC WainwrightReiterated RatingBuy$114.00
3/31/2021Truist FinancialBoost Target$86.00 ➝ $119.00
3/31/2021HC WainwrightReiterated RatingBuy
1/29/2021Royal Bank of CanadaInitiated CoverageOutperform$121.00
1/19/2021HC WainwrightBoost TargetBuy$88.00 ➝ $114.00
12/22/2020WedbushDowngradeOutperform ➝ Neutral$73.00 ➝ $77.00
12/6/2020Piper SandlerBoost TargetOverweight$81.00 ➝ $89.00
7/16/2020Robert W. BairdInitiated CoverageOutperform$90.00
7/1/2020HC WainwrightInitiated CoverageBuy$88.00
6/30/2020Stifel NicolausBoost TargetBuy$67.00 ➝ $95.00
5/28/2020SunTrust BanksInitiated CoverageBuy$86.00
5/8/2020Stifel NicolausBoost TargetBuy$60.00 ➝ $67.00
5/8/2020Piper SandlerBoost TargetOverweight$53.00 ➝ $81.00
4/21/2020WedbushInitiated CoverageOutperform
3/12/2020Wolfe ResearchInitiated CoverageOutperform
2/3/2020Stifel NicolausBoost TargetBuy$52.00 ➝ $32.00
1/6/2020Piper Sandler CompaniesBoost TargetOverweight$26.00 ➝ $53.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 6 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 6 very positive mentions
  • 18 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

IGM Biosciences logo
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Read More

Today's Range

Now: $6.90
Low: $6.76
High: $7.50

50 Day Range

MA: $12.06
Low: $6.90
High: $17.83

52 Week Range

Now: $6.90
Low: $6.17
High: $22.50

Volume

434,862 shs

Average Volume

301,638 shs

Market Capitalization

$410.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.08

Frequently Asked Questions

What sell-side analysts currently cover shares of IGM Biosciences?

The following Wall Street research analysts have issued research reports on IGM Biosciences in the last twelve months: BMO Capital Markets, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Royal Bank of Canada, Stifel Nicolaus, Truist Financial Co., and Wedbush.
View the latest analyst ratings for IGMS.

What is the current price target for IGM Biosciences?

0 Wall Street analysts have set twelve-month price targets for IGM Biosciences in the last year. Their average twelve-month price target is $17.75, suggesting a possible upside of 157.2%. Stifel Nicolaus has the highest price target set, predicting IGMS will reach $27.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $9.00 for IGM Biosciences in the next year.
View the latest price targets for IGMS.

What is the current consensus analyst rating for IGM Biosciences?

IGM Biosciences currently has 1 sell rating, 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IGMS.

What other companies compete with IGM Biosciences?

Other companies that are similar to IGM Biosciences include Evotec, Arcutis Biotherapeutics, Nurix Therapeutics, Arcus Biosciences and Kiniksa Pharmaceuticals. Learn More about companies similar to IGM Biosciences.

How do I contact IGM Biosciences' investor relations team?

IGM Biosciences' physical mailing address is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company's listed phone number is 650-965-7873. The official website for IGM Biosciences is igmbio.com. Learn More about contacing IGM Biosciences investor relations.